5-Amino-1MQ

also known as: 5-Amino-1-methylquinolinium, 5A1MQ, 5-amino-1-methylquinoline

A small-molecule NNMT inhibitor studied in preclinical obesity models for its ability to raise intracellular NAD+ and suppress lipogenesis, with no published human trials as of 2026.

An experimental NNMT inhibitor that raises intracellular NAD+ and SAM and reduces adipocyte fat storage in rodent models; commonly sold alongside peptide stacks for fat loss despite the absence of human safety or efficacy data.

Mechanism of action

Selectively inhibits nicotinamide-N-methyltransferase (NNMT), an enzyme elevated in adipose tissue of obese individuals that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM). NNMT inhibition preserves intracellular NAD+ and SAM pools, suppresses lipogenic transcription factors (PPARγ, C/EBPα, SREBP1), reduces triglyceride accumulation in adipocytes, and may upregulate adiponectin. In rodent studies, it has reduced body weight, adipocyte size, and liver adiposity without affecting food intake.

Primary uses

Experimental fat loss protocols (preclinical rodent data only)
Biohacker stacks for metabolic health (off-label, unstudied in humans)
Research tool for NNMT pathway investigation

Typical dosing

50–150 mg 1x daily (oral (capsule))

Community dosing extrapolated from rodent studies; no human dose has been established through clinical research. Typically taken in cycles of 4–8 weeks.

Regulatory status

Not approved by any regulatory agency for any indication. Sold exclusively as a research chemical. No IND filings or clinical trials registered with ClinicalTrials.gov as of early 2026.

References

[pubmed] Neelakantan H, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochem Pharmacol, 2018;147:141-152.
[review] Liu M, Li L, Chu J, et al. "Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes." Biomed Res Int, 2021;2021:9924314.
[pubmed] Kannt A, et al. "A small molecule inhibitor of nicotinamide N-methyltransferase for the treatment of metabolic disorders." Sci Rep, 2018;8(1):3660.

Related peptides

NAD+

An essential cellular coenzyme that declines with age; now heavily marketed in IV and injectable longevity protocols despite limited randomized clinical evidence for anti-aging claims.

MOTS-c

A mitochondrially encoded peptide studied for its effects on metabolic homeostasis, insulin sensitivity, and exercise capacity.

Tesofensine

A triple-monoamine reuptake inhibitor (SNDRI) with Phase 2 anti-obesity data showing up to ~12% weight loss at 1.0 mg/day — development stalled over cardiovascular concerns; not a peptide and included here for cross-reference only.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.